Hantavirus cardiopulmonary syndrome is an emerging zoonosis in Argentina, which has low incidence but high death rates. No specific pharmacological therapy is available and symptomatic therapy is the only current alternative. This article presents the pathogenesis of hantavirus cardiopulmonary syndrome through a review of clinical experiences in neighbor South American countries, mainly Chile, and the experience acquired at the Infectious Diseases Hospital Francisco Javier Muñiz, Buenos Aires, Argentina. The role of early corticosteroid therapy is discussed taking into account that there is insufficient evidence favoring its use in the hantavirus cardiopulmonary syndrome.
Download full-text PDF |
Source |
---|
One Health Outlook
December 2024
Departamento de Ciencias Biológicas Animales, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Av. Santa Rosa 11735, Santiago, Chile.
PLoS Pathog
November 2024
Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, New Mexico, United States of America.
Vector Borne Zoonotic Dis
January 2025
Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
Microbiol Resour Announc
November 2024
Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
New World orthohantaviruses are rodent-borne tri-segmented viruses that cause hantavirus cardiopulmonary syndrome in humans in the Americas. Molecular diagnostics for orthohantaviruses can be improved with more sequence data. Reported here are completed genomes for Lechiguanas, Maciel, and Laguna Negra viruses.
View Article and Find Full Text PDFArch Virol
August 2024
Fundação Ezequiel Dias (FUNED), Diretoria de Pesquisa e Desenvolvimento, Divisão de Ciência e Inovação, 80 Conde Pereira Carneiro Street, Gameleira, Belo Horizonte, MG, CEP: 30.510-010, Brasil.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!